Psoriasiform Eruption in an Immunocompromised Neurosyphilis Patient

Olivia Lawson; Collins Langley; Michael Davis

doi:10.25251/skin.6.6.17

Olivia Lawson

University of Tennessee Health Science Center College of Medicine

Collins Langley

University of Tennessee Health Science Center College of Medicine

Michael Davis

University of Tennessee Health Science Center College of Medicine

Keywords

Syphilis, immunosuppression, psoriasiform, neurosyphilis

References

1. Baughn RE, Musher DM. Secondary Syphilitic Lesions. Clinical Microbiology Reviews. 2005;18(1):205-216. doi:10.1128/CMR.18.1.205-216.2005

2. Balagula Y, Mattei PL, Wisco OJ, Erdag G, Chien AL. The great imitator revisited: the spectrum of atypical cutaneous manifestations of secondary syphilis. International Journal of Dermatology. 2014;53(12):1434-1441. doi:10.1111/ijd.12518

3. Martins CJ, Lima RB, Eyer-Silva W de A, et al. Secondary syphilis presenting as syphilide psoriasiforme: Lessons from the older syphilology literature. Revista do Instituto de Medicina Tropical de Sao Paulo. 2020;62. doi:10.1590/S1678-9946202062021

PDF

Published

Nov 16, 2022

DOI https://doi.org/10.25251/skin.6.6.17

How to Cite

[1]

Lawson, O., Langley, C. and Davis, M. 2022. Psoriasiform Eruption in an Immunocompromised Neurosyphilis Patient. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), 546–548. DOI:https://doi.org/10.25251/skin.6.6.17.

Issue

Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®

Section

Short Communications

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Similar Articles

Alice B. Gottlieb, April W. Armstrong, Joseph F. Merola, Andrew Napoli, Miroslawa Nowak, Subhashis Banerjee, Thomas Lehman, Philip J. Mease, Impact of Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active Psoriatic Arthritis: Results from a Phase 2 Trial , SKIN The Journal of Cutaneous Medicine: Vol. 8 No. 2 (2024): March 2024 Issue
April W Armstrong, Sang Hee Park, Viktor Chirikov, Pierre Nicolas, Wei-Jhih Wang, Matthew J Colombo, Vardhaman Patel, Optimizing the treatment sequence: the cumulative clinical benefit of treatment initiation with deucravacitinib versus apremilast over 52 weeks in patients with moderate to severe plaque psoriasis from the POETYK PSO-1 trial , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Richard Warren, Howard Sofen, Shinichi Imafuku, Jacek Szepietowski, Andrew Blauvelt, Lynda Spelman, Jessica Toms, Alex Buck, Subhashis Banerjee, Alan Menter, Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Jerry Bagel, April Armstrong, Richard Warren, Kim Papp, Diamant Thaçi, Alan Menter, Jennifer Cather, Matthias Augustin, Lauren Hippeli, Carolin Daamen, Christopher Griffiths, Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Neil Korman, Kim Papp, Jerry Bagel, Peter Foley, Akimichi Morita, Subhashis Banerjee, Elizabeth Colston, Tao Wang, John Throup, Diamant Thaci, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Onset of Action in the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Diamant Thaci, Kenneth Gordon , Melinda Gooderham, Bruce Strober , Neil Korman, Subhashis Banerjee, Subhashis Banerjee, Elizabeth Colston, Jonghyeon Kim, John Throup, Akimichi Morita, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Andrew Blauvelt, Phoebe Rich, Howard Sofen, Jo Lambert, Joseph F Merola, Mark Lebwohl, Thomas Scharnitz, Kim Hoyt, Renata M Kisa, Subhashis Banerjee, Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in scalp, nail, and palmoplantar psoriasis: subgroup analyses of the phase 3 POETYK PSO-1 and PSO-2 trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Jo Lambert, Carle Paul, Alice Gottlieb, Yves Poulin, Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: analysis of body surface area involvement in the phase 3 POETYK PSO-1 and PSO-2 trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Richard Warren , April Armstrong , Melinda Gooderham, Bruce Strober , Diamant Thaci, Shinichi Imafuku, Howard Sofen, Lynda Spelman, Neil Korman, Min Zheng, Elizabeth Colston, John Throup , Sundeep Kundu, Renata Kisa, Subhashis Banerjee, Andrew Blauvelt, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Andrew Blauvelt, Phoebe Rich, Howard Sofen, Jo Lambert, Joe Merola, Mark Lebwohl, Lauren Hippeli, Renata Kisa, Subhashis Banerjee, Alexa Kimball, Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo in scalp, nail, and palmoplantar psoriasis: subset analyses of the phase 3 POETYK PSO-1 and PSO-2 trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 4 (2022): July 2022 Issue

<< < 1 2 3 4 5 > >>

You may also start an advanced similarity search for this article.

Main Article Content

Keywords

References

Article Sidebar

Article Details

Similar Articles